Singapore-headquartered Qritive has integrated its AI modules with US-based Corista's image management platform DP3.
According to a press statement, the combined solution leverages AI to screen for both prostate and colon cancers, quantify IHC markers, and detect lymph node metastasis.
It allows pathologists to prioritise and grade specific cases while improving the detection of hard-to-...
PathAI, maker of AI-enabled pathology products, announced Friday it was partnering with pharma and diagnostics giant Roche.
The strategic partnership will allow PathAI to develop and distribute its AI pathology tech through Roche’s uPath enterprise software, a workflow platform for labs.
The collaboration will begin with distributing PathAI’s research-use-only algorithms through the cloud...
Dutch health tech company Royal Philips today introduced its new enterprise-wide digital pathology platform called IntelliSite.
The product features a suite of scalable software tools designed to streamline workflows, enhance diagnostic confidence, facilitate collaboration, integrate artificial intelligence (AI) and increase the efficiency of pathology labs, Philips said in its announcement....
Paige, a digital pathology diagnostics company, has received De Novo marketing authorization from the Food and Drug Administration for its artificial intelligence software that helps detect prostate cancer.
The Paige Prostate software analyzes digitized biopsy slides and identifies areas that could be cancerous for the pathologist to review further.
“The approval is a landmark achievement in the...
Techcyte raised $21 million in funding for its digital clinical pathology platform. Zoetis, an animal healthcare company and drugmaker, and ARUP Laboratories participated in this round of funding, plus investors from previous rounds.
“Our relationship with Zoetis has been incredible as we’ve revolutionized diagnostics for veterinary clinics,” Ben Cahoon, CEO of Techcyte, said in a statement. “...
Boston-based PathAI is adding a suite of laboratory testing services to its portfolio of artificial intelligence-powered pathology tools through its acquisition of Poplar Healthcare Management.
Poplar Healthcare is a Memphis, Tennessee-based laboratory services provider to a nationwide client base of gastroenterologists, dermatologists, oncologists, urologists, gynecologists and their patients....
Boston-based PathAI, maker of artificial intelligence tools for pathology, has capped off its Series B funding round with a $15 million strategic investment from the Merck Global Health Innovation Fund and Bristol-Myers Squibb. This raise brings the startup’s full round to $75 million, and its total funding to just over $90 million.
WHAT THEY DO
PathAI’s platform employs convolutional neural...
Yesterday PathAI, a Boston-based maker of artificial intelligence tools for pathology, closed a $60 million Series B funding round led by General Atlantic. Other existing investors, most notably General Catalyst, also participated in the round.
To monitor its investment, General Atlantic Managing Director Dr. Michelle Dipp will also be joining the AI company’s board of directors.
WHAT THEY DO...
Deep Lens, a digital pathology startup particularly focused on cancer trials, has brought in a $13.65 million Series A round, according to an SEC filing. The fundraise was headed by Northpond Ventures with additional support from prior investors Rev1 Ventures, Sierra Ventures and Tamarind-Hill Partners, according to a release.
The Series A comes quickly after a seed funding round that raised just...
Columbus, Ohio-based Deep Lens, a digital pathology startup out of Nationwide Children’s Hospital focused on cancer clinical trials, has raised $3.2 million in seed funding. Sierra Ventures led the round with participation from Rev1 Ventures and Tamarin Hill Fund.
With digital pathology, rather than examining a bio specimen with a microscope, a pathologist can study a large number of digitized...
